Abstract
Estimates of residual cardiovascular risks among patients who have experienced a recent acute myocardial infarction (MI) are predominantly derived from secondary prevention trial populations, patient registries, and population-based cohorts. To generate real-world evidence of antiplatelet treatment and recurrent events following MI in patients on antiplatelet treatment among commercial, employer-based insured patients in a large administrative database. This was a retrospective cohort claims database study using the Truven Health MarketScan Commercial Claims and Encounters and Medicare Supplemental databases between 2007-2011. Patients with an acute MI hospitalization with a discharge date between 2008 and 2010 were included. Excluded were those patients with documentation of stroke, transient ischemic attack (TIA), or severe bleeding at or before index hospitalization and with concomitant use of anticoagulant therapy following index hospitalization. Patients treated with clopidogrel following the index MI hospitalization were followed up to 1 year for repeat MI, stroke, and coronary revascularization. Among 33,943 post-MI continuous clopidogrel users without history of stroke, TIA, or bleeding, 22% had diabetes, whereas angina...Continue Reading
References
Jan 8, 1994·BMJ : British Medical Journal
Nov 16, 1996·Lancet·UNKNOWN CAPRIE Steering Committee
Nov 25, 2004·Diabetes Care·Amie T JoyceCharles M Alexander
May 6, 2005·Journal of Managed Care Pharmacy : JMCP·Lida R Etemad, Patrick L McCollam
Sep 7, 2005·JAMA : the Journal of the American Medical Association·Marc S SabatineUNKNOWN Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Dec 12, 2007·Circulation·Elliott M AntmanClyde W Yancy
Jan 16, 2008·Current Medical Research and Opinion·Joseph MenzinMark Friedman
May 14, 2009·JAMA : the Journal of the American Medical Association·Jeffrey S BergerWilliam R Hiatt
Jun 2, 2009·Lancet·UNKNOWN Antithrombotic Trialists' (ATT) CollaborationAlberto Zanchetti
Nov 10, 2009·BMJ : British Medical Journal·Giorgia De BerardisAntonio Nicolucci
Dec 9, 2009·Current Medical Research and Opinion·Karina BerensonJohn Corbelli
Dec 17, 2009·Lancet·Rikke SørensenGunnar H Gislason
Dec 29, 2010·The American Journal of Medicine·David D McManusRobert J Goldberg
Oct 1, 2011·Journal of the American College of Cardiology·Giuseppe PattiGermano Di Sciascio
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Jan 2, 2013·Circulation·Gregory DucrocqPh Gabriel Steg
Mar 5, 2013·Circulation·Jeffrey L AndersonWin-Kuang Shen
Sep 25, 2014·Circulation·Ezra A AmsterdamSusan J Zieman
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 15, 2015·European Heart Journal·Tomas JernbergMagnus Janzon
Mar 31, 2016·Circulation·Glenn N LevineSidney C Smith